ZZPZH(600436) 万联证券·2024-10-22 08:07Investment Rating - The investment rating for the company is "Buy" with a target of outperforming the market by over 15% in the next six months [6][12]. Core Insights - The company reported a revenue of 8.45 billion yuan for the first three quarters of 2024, representing an increase of 11.19% year-on-year, and a net profit attributable to shareholders of 2.69 billion yuan, up 11.73% [3][4]. - The core products, particularly liver disease and cardiovascular medications, showed strong growth, with revenues of 4.28 billion yuan (+20.24%) and 268 million yuan (+11.66%) respectively for the first three quarters [4]. - The company is actively expanding its channel construction, having added over 10,000 new retail outlets through partnerships with major chains [5]. Financial Performance - For Q3 2024, the company achieved a revenue of 2.80 billion yuan (+9.60%) and a net profit of 965 million yuan (+11.73%) [3]. - The overall gross margin for the first three quarters was 45.54%, a decrease of 2.98 percentage points, with liver disease medications showing a gross margin of 70.79% [5][10]. - The forecast for revenue growth is projected at 13.51% for 2024, with net profit expected to reach 3.31 billion yuan, translating to an EPS of 5.49 yuan [6][11]. Product and Market Development - The company has successfully reintroduced the An Gong Niu Huang Wan product, achieving over 100 million yuan in sales, indicating strong demand resilience [4]. - The cosmetics segment also performed well, with a revenue of 525 million yuan (+21.92%) in the first three quarters [4]. - The company is expected to alleviate gross margin pressure through the potential import of raw materials, which may help stabilize costs [5][10].